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Lights at the End of the Tunnel
After years of taking care of patients with psoriasis, it has
become quite obvious to me that a family of factors (gene-
tic, environmental, and infectious) regulates its expression.
The implication of this is that we cannot expect a single
animal model to reproduce the disease or a single target
to serve all novel therapies. In fact, reports from the last
several years about various biologic response modifiers
demonstrate clearly that some patients respond well, while
others (often my patients) seemingly do not, thus supporting
the concept of multiple genetic factors. Into this confusion
of pathogenic models, we now have In this issue, a brief paper
from Joanna Shepherd and her associates from the Division
of Genomic Medicine at the University of Sheffield (p 605).
They report that mice on a BALB/c background with a genetic
absence of the IL-1a receptor antagonist develop a scaling
eruption on the pinnas of each ear. This eruption, which is
acquired as the mice develop adulthood, has a clinical
appearance that resembles psoriasis. Moreover, histological
changes include acanthosis, hyperkeratosis, and infiltrates of
both neutrophils and lymphocytes, all in the right place. This
eruption is limited in its distribution (think elbows and knees or
palms and soles), and it does not occur in all strains of mice.
At the same time, some strains have an associated arthritis
and others have an associated arterial inflammation. We
predict that ultimately there will be many models of psoriasis
because its pathogenesis may not be singular. As we reach
the end of the tunnel, there is more than one light.
Deja Vu all Over Again (Attributed to Yogi
Berra, New York Yankees)
Thirty-five years ago, most dermatologists and prospective
dermatologists in the USA invested 2 years of their lives in
the service of their country, some as trainees at the National
Institutes of Health and many others as practising physicians
in the military. One of the realities of military service was the
need to deal with the many African-American servicemen
who suffered from the hair follicle disorder pseudofolliculitis
barbae. We knew at the time that a closely cropped beard
would lead (after several weeks in transition) to complete
resolution, but this was largely unacceptable to our military
superiors. You can imagine the tension, especially for military
personnel who had already survived the horrors of one year
in Viet Nam and were ‘‘marking time’’ in their terminal year of
service. Not only did we know that once hair shafts were
liberated from the follicle, the disorder would remit, but also
that the presence of tightly coiled hair shafts was not the only
factor, since some men had the disease and others did not.
Thirty-five years later, an impressively multinational collection
of investigators and clinicians have come together to provide
at least one answer. In this issue, Winter and Schweizer and
their colleagues from around the world demonstrate that a
single nucleotide polymorphism for a protein expressed in
the inner root sheath of hair follicles plays a major role in the
expression of pseudofolliculitis (p 652). The idea is that this
‘‘defect’’ disrupts the ‘‘guiding’’ nature of the follicle itself. It is
particularly noteworthy that the patients who served as the
core of the well-defined clinical populations examined in this
study are the descendants of the patients we struggled to
help in 1970. This paper also illustrates graphically the
complex fashion in which several genetic and environmental
factors may conspire to produce disease. We salute the
service personnel who work under extraordinarily difficult
conditions to serve, the military physicians who help to
care for them, and of course the scientists who conduct
experiments that address important questions.
Out of Left Field
It is appropriate to continue the baseball allusion, since the
unanticipated seems to come ‘‘out of left field’’ and since
Japan and Cuba are the only major countries in which baseball
remains the national pastime. In this issue, a surprising paper
from Masaaki Yoshikawa and his associates at two prominent
agricultural institutions in Japan provides surprising data to
indicate that an orally administered soy-derived peptide
inhibits the acute alopecia caused by etoposide to a
substantial degree (p 848). First, those who take care of
patients with hair disorders can attest to the incredible
importance of hair in our cultures. I suspect that money spent
on hair in Japan, the USA, or in Europe would exceed by far
the entire economy of Cuba, and it is certainly larger than the
economy of baseball worldwide. Likewise, the capacity of anti-
cancer drugs to cause alopecia is both recognized and feared.
But a derivative of soy beans? Orally administered? And from
experts in Food Science? Who would have thought? This
process of discovery is exactly what members of Congress in
the United States need to know, that the path of discovery is
unpredictable and that only under unusual circumstances is it
useful to ‘‘plan’’ for it. We tip our hat to the inquisitive and
obviously well-informed scientists from Japan who have put
something new together, to leaders in our own institutions who
emphasize the importance of basic research, to our collea-
gues in the USA who are attempting to measure ‘‘the burden’’
of skin disease (including alopecia), and to an imaginative
Editor, who has the insight to accept a letter from ‘‘left field.’’
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